A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Latest Information Update: 03 Jul 2024
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DurvaRad
- 04 Jun 2024 Results assessing safety and efficacy of Durvalumab and stereotactic ablative body radiotherapy in locally advanced and borderline resectable pancreatic cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 Jun 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 23 Jun 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.